TY - JOUR
T1 - Advancing paediatric allergy care
T2 - key findings from the largest trial of house dust mite sublingual immunotherapy-tablets in children
AU - Schoos, Ann Marie Malby
AU - Chawes, Bo
PY - 2025
Y1 - 2025
N2 - Allergic rhinitis and rhinoconjunctivitis (AR/C) caused by house dust mites (HDM) significantly burden children's daily lives.1 Despite allergen reduction and pharmacotherapy, many children experience substantial symptoms and impaired quality of life,2 highlighting the need for disease-modifying treatments like allergen immunotherapy (AIT). In this issue, Schuster et al.3 present compelling results from the largest double-blind, placebo-controlled trial of SQ HDM sublingual immunotherapy (SLIT)-tablets or placebo for one year in children aged 5–11 years (n = 1460) with physician-diagnosed HDM AR/C from 95 sites across Europe and North America. The primary outcome was the Total Combined Rhinitis Score during the final 8 weeks of treatment, where a 22% reduction was demonstrated with the HDM SLIT-tablet compared to placebo (absolute difference, 1.0, 95% CI: 0.5–1.4; p < 0.0001), which exceeds the minimal clinically important difference of 15%
AB - Allergic rhinitis and rhinoconjunctivitis (AR/C) caused by house dust mites (HDM) significantly burden children's daily lives.1 Despite allergen reduction and pharmacotherapy, many children experience substantial symptoms and impaired quality of life,2 highlighting the need for disease-modifying treatments like allergen immunotherapy (AIT). In this issue, Schuster et al.3 present compelling results from the largest double-blind, placebo-controlled trial of SQ HDM sublingual immunotherapy (SLIT)-tablets or placebo for one year in children aged 5–11 years (n = 1460) with physician-diagnosed HDM AR/C from 95 sites across Europe and North America. The primary outcome was the Total Combined Rhinitis Score during the final 8 weeks of treatment, where a 22% reduction was demonstrated with the HDM SLIT-tablet compared to placebo (absolute difference, 1.0, 95% CI: 0.5–1.4; p < 0.0001), which exceeds the minimal clinically important difference of 15%
U2 - 10.1016/j.lanepe.2024.101167
DO - 10.1016/j.lanepe.2024.101167
M3 - Comment/debate
C2 - 39759886
AN - SCOPUS:85211630630
VL - 48
JO - The Lancet Regional Health - Europe
JF - The Lancet Regional Health - Europe
SN - 2666-7762
M1 - 101167
ER -